| 1 |
35050407 | Impact of tolvaptan on improvement of tricuspid regurgitation and right ventricular dimension in patients with right-sided heart failure. | 2022 Jul |
2 |
| 2 |
35110480 | Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics. | 2022 Feb 1 |
1 |
| 3 |
35134221 | An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. | 2022 Apr 25 |
1 |
| 4 |
35165806 | Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease. | 2022 Jun |
1 |
| 5 |
35314480 | Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial. | 2022 Apr |
1 |
| 6 |
35371438 | Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome. | 2022 Apr |
1 |
| 7 |
35503085 | Exploiting dependence of castration-resistant prostate cancer on the arginine vasopressin signaling axis by repurposing vaptans. | 2022 May 3 |
1 |
| 8 |
32901255 | Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial. | 2021 May 27 |
1 |
| 9 |
32957887 | Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study. | 2021 |
1 |
| 10 |
33904139 | Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome. | 2021 Nov |
2 |
| 11 |
33920088 | Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. | 2021 Apr 10 |
1 |
| 12 |
34039465 | Characterization of tolvaptan response and its impact on the outcome for patients with heart failure. | 2021 Oct |
2 |
| 13 |
34070416 | Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. | 2021 May 25 |
1 |
| 14 |
34094612 | Tolvaptan Response in a Hyponatremic Newborn with Syndrome of Inappropriate Secretion of Antidiuretic Hormone. | 2021 |
1 |
| 15 |
34309184 | A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites. | 2021 Dec |
1 |
| 16 |
34480075 | The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial. | 2021 Sep 3 |
1 |
| 17 |
34514204 | Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD. | 2021 Sep |
2 |
| 18 |
34540466 | Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management. | 2021 Aug |
1 |
| 19 |
34719623 | Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. | 2021 |
1 |
| 20 |
34884753 | Updates and Perspectives on Aquaporin-2 and Water Balance Disorders. | 2021 Nov 30 |
1 |
| 21 |
34955900 | The Role of Vasopressin V2 Receptor in Drug-Induced Hyponatremia. | 2021 |
1 |
| 22 |
31616061 | Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. | 2020 Feb |
2 |
| 23 |
31909447 | Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling. | 2020 Jan 6 |
1 |
| 24 |
32138675 | Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study. | 2020 Mar 5 |
1 |
| 25 |
32232633 | Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. | 2020 Jul |
1 |
| 26 |
32335259 | Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. | 2020 Aug |
1 |
| 27 |
32518862 | The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. | 2020 Jun |
1 |
| 28 |
32665162 | Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure. | 2020 Nov |
1 |
| 29 |
32683063 | Pharmacological Dilutional Therapy Using the Vasopressin Antagonist Tolvaptan for Young Patients With Cystinuria: A Pilot Investigation. | 2020 Oct |
1 |
| 30 |
33009446 | Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. | 2020 Oct 2 |
1 |
| 31 |
33033683 | Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience. | 2020 Sep 2 |
1 |
| 32 |
33208569 | Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites. | 2020 Dec |
2 |
| 33 |
33308138 | Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. | 2020 Dec 11 |
1 |
| 34 |
30210135 | Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure. | 2019 Feb 15 |
1 |
| 35 |
30242840 | NHA2 promotes cyst development in an in vitro model of polycystic kidney disease. | 2019 Jan |
1 |
| 36 |
30284699 | Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. | 2019 Jan |
1 |
| 37 |
30312449 | Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers? | 2019 Jan 1 |
1 |
| 38 |
30504136 | Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. | 2019 Feb |
1 |
| 39 |
30578153 | Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan. | 2019 Mar |
1 |
| 40 |
30625470 | Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites. | 2019 |
1 |
| 41 |
30689194 | Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. | 2019 Feb |
1 |
| 42 |
30801659 | Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor-independent pathway. | 2019 May |
1 |
| 43 |
30873020 | Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor. | 2019 |
2 |
| 44 |
30898339 | Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. | 2019 Jul |
1 |
| 45 |
31019162 | A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study. | 2019 May 12 |
1 |
| 46 |
31161520 | Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. | 2019 Sep |
1 |
| 47 |
31484861 | A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure. | 2019 Sep 27 |
1 |
| 48 |
28379536 | Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. | 2018 Mar 1 |
1 |
| 49 |
28455745 | Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? | 2018 Mar |
2 |
| 50 |
29204517 | Proteomic analysis of AQP11-null kidney: Proximal tubular type polycystic kidney disease. | 2018 Mar |
1 |